Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions
about
sameAs
Extracellular signal-regulated kinase induces the megakaryocyte GPIIb/CD41 gene through MafB/KreislerThe inhibitory activity of ginsenoside Rp4 in adenosine diphosphate-induced platelet aggregationIntegrin alphaIIbbeta3:ligand interactions are linked to binding-site remodeling.12-lipoxygenase: a potential target for novel anti-platelet therapeutics.Volatile anesthetics, not intravenous anesthetic propofol bind to and attenuate the activation of platelet receptor integrin αIIbβ3.A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor microenvironment.Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and AktVasodilator-stimulated phosphoprotein-phosphorylation by ginsenoside Ro inhibits fibrinogen binding to αIIb/β3 in thrombin-induced human platelets.Platelet Integrin αIIbβ3 Inhibitor Rescues Progression of Apoptosis in Human Platelets.Quantification of integrin receptor agonism by fluorescence lifetime imaging.Anti-platelet and Anti-thrombotic Effects of a Poly-ingredient formulation: In vitro and in vivo experimental evidences.Bitistatin-functionalized fluorescent nanodiamond particles specifically bind to purified human platelet integrin receptor αIIbβ3 and activated platelets.New mechanisms of antiplatelet activity of nifedipine, an L-type calcium channel blocker.Novel antibodies against GPIbα inhibit pulmonary metastasis by affecting vWF-GPIbα interaction
P2860
Q24567630-886478B4-EBB0-4AFD-A066-719F61E38FF9Q28817701-131C1A34-C935-4EC7-A794-CD3A85A26A4CQ33252264-B764EE23-D2A2-45B4-936C-FC207DE96D4DQ34207687-A9C12F03-BCEF-44B2-A367-55041CFFA7B2Q34661939-3D6ECAAA-B149-49D6-BFA6-8CEE2FA25B8DQ36305346-78034919-1449-453B-B873-E00325D03316Q36437891-A1E44A11-F1E8-44DD-BCE0-5681AA76B326Q37314349-18BF2C96-CD08-44D7-BE20-B71BACF20657Q37412613-B8A223BA-9A24-4008-B859-65707C4D4C90Q38294282-BFA2B783-BEF7-4A67-9C15-26AD9E4169C0Q41294355-DF88450A-682D-48C2-A011-576B573E115AQ42252106-306C4346-1544-4483-AF8A-0DFE6DE46393Q42592882-67C9989C-0AF2-4A6C-A40D-CBD59133DEFBQ58732980-5CD395D9-92EE-417A-A1F6-889B09306836
P2860
Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@ast
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@en
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@nl
type
label
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@ast
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@en
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@nl
prefLabel
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@ast
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@en
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@nl
P1476
Platelet glycoprotein IIb/IIIa ...... l trials and future directions
@en
P2093
Jacques R Leclerc
P304
P356
10.1097/00003246-200205001-00025
P407
P433
P577
2002-05-01T00:00:00Z